Annexon's (ANNX) Sell (D-) Rating Reiterated at Weiss Ratings

Key Points

• Annexon (NASDAQ:ANNX) had its "sell (D-)" rating reaffirmed by Weiss Ratings, indicating continuing concerns about the company's stock performance.
• Analysts from Zacks Research upgraded the stock from "strong sell" to "hold," while HC Wainwright maintained a "buy" rating with a price target of $14.00.
• Annexon recently reported a quarterly earnings per share of ($0.34), which exceeded expectations, with analysts forecasting a full-year EPS of ($0.96).

Annexon (NASDAQ:ANNX - Get Free Report)'s stock had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings in a research note issued to investors on Wednesday,Weiss Ratings reports.

Several other research analysts also recently commented on the company. Zacks Research raised Annexon from a "strong sell" rating to a "hold" rating in a research report on Monday, August 18th. HC Wainwright reaffirmed a "buy" rating and issued a $14.00 price target on shares of Annexon in a research report on Friday, August 15th. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $12.50.

Annexon Price Performance

Shares of ANNX stock traded up $0.08 during trading on Wednesday, reaching $3.15. The company had a trading volume of 1,227,328 shares, compared to its average volume of 1,632,295. The firm's 50 day simple moving average is $2.51 and its two-hundred day simple moving average is $2.27. Annexon has a one year low of $1.28 and a one year high of $7.85. The company has a market capitalization of $346.15 million, a PE ratio of -2.44 and a beta of 1.36.

Annexon (NASDAQ:ANNX - Get Free Report) last issued its quarterly earnings data on Thursday, August 14th. The company reported ($0.34) earnings per share for the quarter, beating analysts' consensus estimates of ($0.36) by $0.02. Analysts forecast that Annexon will post -0.96 earnings per share for the current year.

Institutional Trading of Annexon

Institutional investors have recently bought and sold shares of the stock. Nuveen LLC acquired a new stake in Annexon in the 1st quarter valued at $670,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in Annexon in the 4th quarter valued at $252,000. California State Teachers Retirement System boosted its stake in Annexon by 849.0% in the 4th quarter. California State Teachers Retirement System now owns 66,375 shares of the company's stock valued at $341,000 after buying an additional 59,381 shares in the last quarter. Wellington Management Group LLP boosted its stake in Annexon by 32.9% in the 1st quarter. Wellington Management Group LLP now owns 356,480 shares of the company's stock valued at $688,000 after buying an additional 88,314 shares in the last quarter. Finally, XTX Topco Ltd boosted its stake in Annexon by 65.4% in the 1st quarter. XTX Topco Ltd now owns 58,130 shares of the company's stock valued at $112,000 after buying an additional 22,979 shares in the last quarter.

About Annexon

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.